Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (1): 42-46.doi: 10.3969/j.issn.1000-6621.2021.01.009
• Original Articles • Previous Articles Next Articles
LUO Xiao-qing, DUAN Si-yu, LIN Ming-yu, DENG Xun, LIU Bi-fen, LI Lian, TANG Hui-wen, DING Li()
Received:
2020-12-06
Online:
2021-01-10
Published:
2021-01-12
Contact:
DING Li
E-mail:dingli@mail.sysu.edu.cn
LUO Xiao-qing, DUAN Si-yu, LIN Ming-yu, DENG Xun, LIU Bi-fen, LI Lian, TANG Hui-wen, DING Li. Nutritional risk screening and influencial factor analysis in hospitalized patients with comorbidity of tuberculosis and diabetes mellitus[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 42-46. doi: 10.3969/j.issn.1000-6621.2021.01.009
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.01.009
因素 | 无营养风险组(134例) | 有营养风险组(35例) | 统计检验值 | P值 | |||
---|---|---|---|---|---|---|---|
性别[例数(构成比,%)] | χ2=0.938 | 0.333 | |||||
男 | 106(79.10) | 25(71.43) | |||||
女 | 28(20.90) | 10(28.57) | |||||
年龄组(岁)[例数(构成比,%)] | χ2=2.332 | 0.506 | |||||
20~ | 9(6.72) | 2(5.72) | |||||
40~ | 57(42.54) | 13(37.14) | |||||
60~ | 64(47.76) | 17(48.57) | |||||
80~90 | 4(2.98) | 3(8.57) | |||||
BMI[例数(构成比,%)] | χ2=55.899 | 0.000 | |||||
<18.5 | 0(0.00) | 13(37.14) | |||||
18.5~ | 93(69.40) | 19(54.29) | |||||
≥24 | 41(30.60) | 3(8.57) | |||||
结核类型[例数(构成比,%)] | χ2=0.245 | 0.881 | |||||
肺结核 | 123(91.79) | 33(94.28) | |||||
肺外结核 | 5(3.73) | 1(2.86) | |||||
肺结核并发肺外结核 | 6(4.48) | 1(2.86) | |||||
患者类型[例数(构成比,%)] | χ2=0.000 | 0.984 | |||||
初治 | 107(79.85) | 28(80.00) | |||||
复治 | 27(20.15) | 7(20.00) | |||||
结核分枝杆菌检出情况[例数(构成比,%)] | χ2=0.018 | 0.895 | |||||
菌阴 | 33(24.63) | 9(25.71) | |||||
菌阳 | 101(75.37) | 26(74.29) | |||||
并发症[例数(构成比,%)] | χ2=0.389 | 0.533 | |||||
有 | 61(45.52) | 18(51.43) | |||||
无 | 73(54.48) | 17(48.57) | |||||
病程(T1)[例数(构成比,%)] | χ2=20.262 | 0.000 | |||||
T1≤1个月 | 57(42.54) | 3(8.57) | |||||
T1>1个月 | 77(57.46) | 32(91.43) | |||||
抗结核治疗时间(T2))[例数(构成比,%)] | χ2=0.813 | 0.666 | |||||
未进行抗结核治疗 | 73(54.48) | 20(57.14) | |||||
0<T2≤2个月 | 57(42.54) | 13(37.14) | |||||
T2>2个月 | 4(2.98) | 2(5.72) | |||||
Hb[g/L,M(Q1,Q3)] | 133.50(119.25,146.00) | 119.00(105.25,127.00) | U=-3.838 | 0.000 | |||
ALB[g/L,M(Q1,Q3)] | 40.45(35.83,43.05) | 34.30(28.63,38.93) | U=-4.244 | 0.000 | |||
PAB(g/L, | 187.01±32.42 | 127.78±39.76 | t=4.051 | 0.000 | |||
FBS[mmol/L,M(Q1,Q3)] | 7.45(6.20,10.50) | 8.75(6.55,9.78) | U=-0.333 | 0.739 | |||
GHB [%,M(Q1,Q3)] | 8.05(6.93,10.48) | 7.30(6.48,9.73) | U=-0.217 | 0.828 | |||
NLR[M(Q1,Q3)] | 2.98(2.45,4.35) | 3.73(2.22,5.25) | U=-2.405 | 0.016 | |||
PNI[M(Q1,Q3)] | 46.68(42.73,50.39) | 40.98(35.39,47.45) | U=-4.215 | 0.000 | |||
体质量[kg,M(Q1,Q3)] | 60.00(55.00,68.98) | 57.15(48.75,68.50) | U=-4.032 | 0.000 | |||
平均BMI[M(Q1,Q3)] | 22.34(20.30,24.00) | 21.39(18.27,23.84) | U=-4.424 | 0.000 | |||
住院天数[d,M(Q1,Q3)] | 8.00(6.00,12.00) | 8.50(7.00,11.25) | U=-1.777 | 0.076 |
[1] |
Girardi E, Sañé Schepisi M, Goletti D, et al. The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. Int J Infect Dis, 2017,56:45-53. doi: 10.1016/j.ijid.2017.01.018.
doi: 10.1016/j.ijid.2017.01.018 URL pmid: 28153793 |
[2] | 冯治宇, 谭守勇, 章志俊, 等. 营养支持对伴营养不良的肺结核并肺部感染者的疗效观察. 临床肺科杂志, 2018,23(7):1169-1171. doi: 10.3969/j.issn.1009-6663.2018.07.002. |
[3] | 邵立群, 赵飒. 营养治疗对2型糖尿病合并肺结核患者的影响. 中国现代药物应用, 2018,12(14):185-186. doi: 10.14164/j.cnki.cn11-5581/r.2018.14.108. |
[4] | 林宏, 范志斌. 营养支持及饮食干预对肺结核合并糖尿病患者的干预效果. 慢性病学杂志, 2019,20(12):1867-1868,1871. doi: 10.16440/j.cnki.1674-8166.2019.12.036. |
[5] | 刘相花. 探究护理干预对肺结核合并糖尿病患者生活质量的影响. 糖尿病新世界, 2020,23(14):120-122. doi: 10.16658/j.cnki.1672-4062.2020.14.120. |
[6] | 马亮亮. 糖尿病合并肺结核患者营养状况与肺功能的相关性研究. 中外医学研究, 2020,18(12):180-182. doi: 10.14033/j.cnki.cfmr.2020.12.076. |
[7] |
Kondrup J, Allison SP, Elia M, et al. Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr, 2003,22(4):415-421. doi: 10.1016/s0261-5614(03)00098-0.
doi: 10.1016/S0261-5614(03)00098-0 URL |
[8] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09. |
[9] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09. |
[10] |
American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care, 2010,33 Suppl 1: S11-61. doi: 10.2337/dc10-S011.
doi: 10.2337/dc10-S011 URL |
[11] | 许静涌, 杨剑, 康维明, 等. 营养风险及营养风险筛查工具营养风险筛查2002临床应用专家共识(2018版). 中华临床营养杂志, 2018,26(3):131-135. doi: 10.3760/cma.j.issn.1674-635X.2018.03.001. |
[12] | 陈梅英, 吴蓓蓓, 陈小红, 等. 多学科联合诊疗模式营养支持在肺结核合并糖尿病患者中的应用. 实用临床医药杂志, 2020,24(1):95-98. doi: 10.7619/jemp.202001024. |
[13] | 盛培培. 肺结核合并糖尿病患者的临床治疗分析. 糖尿病新世界, 2020,23(1):193-194. doi: 10.16658/j.cnki.1672-4062.2020.01.193. |
[14] | 孙凤. 初治、复治肺结核合并2型糖尿病患者的营养状况调查. 临床肺科杂志, 2010,15(1):18-19. doi: 10.3969/j.issn.1009-6663.2010.01.009. |
[15] |
Okamura K, Nagata N, Wakamatsu K, et al. Hypoalbuminemia and lymphocytopenia are predictive risk factors for in-hospital mortality in patients with tuberculosis. Intern Med, 2013,52(4):439-444. doi: 10.2169/internalmedicine.52.8158.
doi: 10.2169/internalmedicine.52.8158 URL pmid: 23411698 |
[16] | 李亚伦, 李镭, 张立, 等. 血清白蛋白及尿素氮水平与肺癌不同临床病理特征和预后的关系. 中国肺癌杂志, 2017,20(3):175-186. doi: 10.3779/j.issn.1009-3419.2017.03.06. |
[17] | 毛毅, 陈怡, 吴桂辉, 等. 肺结核患者营养风险与临床特征的相关性分析. 结核与肺部疾病杂志, 2020,1(2):24-28. doi: 10.3969/j.issn.2096-8493.2020.01.006. |
[18] | 田雨, 王化虹, 李俊霞, 等. 炎症性肠病营养风险和营养治疗方案选择的回顾性分析. 肠外与肠内营养, 2018,25(2):98-101,106. doi: 10.16151/j.1007-810x.2018.02.009. |
[19] |
Mupfumi L, Moyo S, Molebatsi K, et al. Correction: Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana. PLoS One, 2018,13(6):e0198711. doi: 10.1371/journal.pone.0198711.
doi: 10.1371/journal.pone.0198711 URL pmid: 29856867 |
[20] | 陈薇, 丁芹, 顾颖, 等. 上海市900例老年住院结核病患者营养状况调查分析. 中国防痨杂志, 2020,42(7):725-730. doi: 10.3969/j.issn.1000-6621.2020.07.015. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||